



**Abbott**


**ABBOTT**

**Exceptional Track Record of Creating  
Long Term Shareholder Value**

## FORWARD LOOKING STATEMENT

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

# Framework for Long Term Value Creation



Balance

---

Relevance

---

Global Presence

---

Financial Performance

---

# Leadership in the Diverse Areas of Healthcare

## EPD

- Leading positions in India, Russia and Latin America
- 

## NUTRITION

- #1 Adult Nutrition
  - #1 in U.S. Pediatric Nutrition
- 

## DIAGNOSTICS

- Industry leader in Core Lab, Molecular and Point-of-Care
  - #1 Blood Screening
- 

## MEDICAL DEVICES


- #1 or #2 positions in Coronary Stents, Cardiac Rhythm Management, Electrophysiology and Heart Failure
  - Strong positions in Neuromodulation and Diabetes Care
- 



# Aligned with Global Trends

## AGING POPULATION GLOBALLY

% of Global Population > 65 years old




Source: U.S. Census Bureau "An Aging World": 2015

# Aligned with Global Trends

## GROWTH IN EMERGING MARKETS

- Investing in healthcare
- Emerging middle class



Sources: The World Bank World Development Indicators  
Excel Funds Emerging Markets vs. Developed Markets


# Nutrition

## SCIENCE-BASED NUTRITION FOR EVERY STAGE OF LIFE

- #1 Pediatric in U.S.; other geographies
- #1 Adult Nutrition globally
- Uniquely balanced across products and geographies

### STRATEGIC PRIORITIES

- Build strong globally recognized brands
- Capture share with innovation
- Grow and shape markets




# Branded Generic Pharmaceuticals

## FOCUSED GROWTH IN EMERGING MARKETS

- 100% focused on emerging markets
- Leading positions in India, Russia and Latin America
- Delivering strong sales growth

### STRATEGIC PRIORITIES

- Strengthening local presence and capabilities
- Market-specific innovation
- Building locally-relevant portfolios in key therapeutic areas




# Diagnostics

## INNOVATIVE SOLUTIONS TO IMPROVE CARE

- Leading platforms in Core Laboratory, Point-of-Care and Molecular diagnostics

### STRATEGIC PRIORITIES

- Launch next-generation Alinity systems
- Continue to expand in priority emerging markets
- Continue to drive above-market growth in developed markets



# Medical Devices

## CREATING A GLOBAL LEADER

- Leading positions in cardiovascular, neuromodulation and diabetes care
- #1 or #2 in several large and high-growth cardiovascular device markets
- Industry-leading pipeline

### STRATEGIC PRIORITIES

- Effectively integrate Abbott and St. Jude Medical businesses
- Capture share in large established segments
- Shape and grow emerging categories

### CARDIOVASCULAR



### NEUROMODULATION



### DIABETES



# Leading Pipeline of Customer-Focused Innovation

## NUTRITION



## ESTABLISHED PHARMACEUTICALS



## DIAGNOSTICS



## MEDICAL DEVICES




# Abbott

## CREATING LONG TERM SHAREHOLDER VALUE

- Broad and balanced portfolio
- Market-leading positions
- Global presence and scale
- Delivering innovation that creates value
- Strong financial performance





**Abbott**